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A B S T R A C T
Purpose: The growing recognition of epilepsies and encephalopathies associated with autoantibodies
against surface neuronal proteins (LGI1, NMDAR, CASPR2, GABABR, and AMPAR) means that
epileptologists are increasingly asking questions about mechanisms of antibody-mediated epileptogen-
esis, and about the use of immunotherapies. This review summarizes clinical and paraclinical
observations related to autoimmune epilepsies, examines the current evidence for the effectiveness of
immunotherapy, and makes epilepsy-speciﬁc recommendations for future research.
Method: Systematic literature search with summary and review of the identiﬁed publications. Studies
describing the clinical characteristics of autoantibody-associated epilepsies and treatments are detailed
in tables.
Results: Literature describing the clinical manifestations and treatment of autoimmune epilepsies
associated with neuronal cell-surface autoantibodies (NSAbs) is largely limited to retrospective case
series. We systematically summarize the features of particular interest to epileptologists dividing
patients into those with acute or subacute encephalopathies associated with epilepsy, and those with
chronic epilepsy without encephalopathy. Available observational studies suggest that immunothera-
pies are effective in some clinical circumstances but outcome data collection methods require greater
standardization.
Conclusions: The clinical experience captured suggests that clusters of clinical features associate well
with speciﬁc NSAbs. Intensive and early immunotherapy is indicated when patients present with
autoantibody-associated encephalopathies. It remains unclear how patients with chronic epilepsy and
the same autoantibodies should be assessed and treated. Tables in this paper provide a comprehensive
resource for systematic descriptions of both clinical features and treatments, and highlight limitations of
current studies.
 2016 The Authors. Published by Elsevier Ltd on behalf of British Epilepsy Association. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
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It has long been recognized that patients with autoantibody-
associated systemic disorders (especially Systemic Lupus Erythe-
matosus and Sjo¨gren’s Syndrome) have an increased risk of epilepsy
[1]. In these conditions, the link with epilepsy is likely to be
multifactorial and not solely related to direct actions of antibodies
on neurons. Over the last decade, however, it has become clear that
there are also a number of autoimmune conditions which present
with epilepsy plus other neuropsychiatric manifestations, that are
characterized by speciﬁc autoantibodies directed against neuronal* Corresponding author.
E-mail address: sarosh.irani@ndcn.ox.ac.uk (S.R. Irani).
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creativecommons.org/licenses/by-nc-nd/4.0/).targets. The study of these autoantibodies is especially informative
as their speciﬁc molecular targets are likely to inform the
mechanisms of epileptogenesis in humans. This review focuses
on these emerging conditions as they now feature in the differential
diagnosis of many other neurological and psychiatric disorders,
especially those associated with epilepsy (Table 1). The targets of
the major epilepsy-associated antibodies include the extracellular
domains of neuronal proteins such as leucine-rich glioma
inactivated-1 (LGI1), contactin-associated protein like 2 (CASPR2),
the N-methyl-D-aspartate receptor (NMDAR) and the gamma
aminobutyric acid receptor, plus intracellular molecules such as
glutamic acid decarboxylase (GAD) [2–7].
Neuronal cell-surface antibodies (NSAbs) are detected using
various techniques such as immunohistochemistry, radioimmu-
noassays and cell-based assays [8]. Some NSAbs have not only been Association. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Disorders which may mimic autoimmune encephalopathies.
Differential diagnosis Clinical features
Infections Herpes simplex encephalitis Fever, headache, personality change, seizures, memory loss,
focal signs
HIV Seizures, psychosis, sleep disturbance, amnesia
Enterovirus Drowsiness, cerebellar ataxia, seizures
Psychiatric disorders Depression Poor concentration, irritability, insomnia, fatigue, suicidal
ideations
Schizophrenia Hallucinations, delusions, speech problems and limited
cognitive impairment
Bipolar disorder Irritability, insomnia, fatigue, poor concentration
Inﬂammation Cerebral vasculitis Headache, confusion, seizures, focal signs
Hashimoto’s encephalopathy Psychosis, myoclonus, tremor, poor concentration, amnesia
Structural lesions Brain tumour, for example Headache, vomiting, seizures, focal signs
Toxic/metabolic encephalopathy Electrolyte imbalances (e.g. renal/liver/glucose) Seizures, confusion, weakness, coma, muscle cramps
Drugs (e.g. ketamine/cocaine) Insomnia, confusion, nausea and vomiting
Wernicke-Korsakoff syndrome Confusion, amnesia, confabulation, ophthalmoplegia, ataxia
Degenerative Creutzﬁeld Jakob or rapid forms of Lewy Body or
Alzheimer’s disease
Amnesia, sleep fragmentation, myoclonus, anxiety, depression,
visual hallucinations, parkinsonism
O.D. Bakpa et al. / Seizure 41 (2016) 26–41 27associated with epilepsy but also with other neurological
manifestations involving the peripheral nervous system (for
example neuromyotonia) or the central nervous system (for
example psychosis and amnesia) [8–12]. The likely pathogenic role
of these NSAbs is suggested by observations such as the temporal
association between clinical improvement and reductions in
antibody levels, the presence of these antibodies in cerebrospinal
ﬂuid (CSF), and early in vitro and in vivo animal experiments which
use the human antibodies to reproduce aspects of the human
disease. Increasing recognition of these autoantibody-mediated
disorders may require some novel approaches to fundamentals of
epilepsy including:
1. a partial reclassiﬁcation of the aetiologies of epilepsies [13] with
a focus on the diagnosis and deﬁnition of antibody-mediated
epilepsies
2. the need to identify which patients with refractory or new-onset
epilepsies may beneﬁt from autoantibody testing, and
3. a more detailed understanding of the potential role for
immunotherapy (IT) in the management of antibody-associated
epilepsies.
We approach these issues by combining a systematic literature
search with a review of the ﬁndings, and detailed reference
summary tables. Our main focus is the use of ITs in the
management of autoantibody-associated epilepsies. However,
before addressing these treatment-related questions, we summa-
rize current knowledge about the typical presentations of
autoimmune encephalitis, with a focus on the epileptic pheno-
types seen in these disorders and the range of associated
neuropsychiatric manifestations. Subsequently, we discuss the
signiﬁcance of autoantibodies in patients with seizures in different
clinical settings. In this way, our review also aims to improve
recognition and diagnosis of these potentially treatable syn-
dromes.
2. Methods
We conducted a systematic search of PUBMED for articles
published between January 1995 to April 2015 using the search
terms ‘antibodies and epilepsy, VGKC and epilepsy, NMDA and
epilepsy, AMPA and epilepsy, GAD and epilepsy’. The search was
limited to articles in English. The list of identiﬁed articles was
complemented by additional searches for relevant articles in the
reference section of the publications captured by the initial search.References relating to IgA or IgM antibodies have not been
included.
3. Results
567 studies were identiﬁed of which 34 were most relevant to
this review (Table 2). The studies identiﬁed were observational
studies and case reports. No controlled clinical trials were
identiﬁed. The studies included describe a total of 1451 patients
(182 male, 767 female, 502 gender not speciﬁed) with clinical
presentations of antibody-associated epilepsies. Patient ages
ranged from 2 to 92 years (median age 23). Most case series or
patient groups were small, but ranged from 3 to 577 cases. Most
patients described had a concomitant neuropsychiatric syndrome
consistent with an encephalopathy.
4. Clinical characteristics of autoimmune epilepsies
The autoimmune encephalopathies associated with seizures
and antibodies to LGI1, GAD and the NMDA-, AMPA-, and GABAB-
receptors are summarized in Table 3, and described in more detail
below with a particular focus on the aspects most relevant to
epileptology.
4.1. Syndromes associated with LGI1-, CASPR2- and VGKC-complex-
antibodies
The clinical features, radiological and CSF ﬁndings of patients
with these antibodies are summarized in Table 2a. The nomencla-
ture of these antibodies in the literature appears complex and is
summarized below.
Since 2010, it has become apparent that ‘VGKC-complex’
antibodies principally target the extracellular domains of LGI1, and
less frequently CASPR2 [14]. Patients with antibodies against these
two components of the VGKC-complex may be differentiated by
some clinical features. For example, the presence of faciobrachial
dystonic seizures (FBDS) and hyponatraemia strongly suggest
LGI1-reactivity, whereas the presence of neuromyotonia or other
features of Morvan’s syndrome suggest CASPR2-directed auto-
antibodies (sometimes accompanied by LGI1-antibodies). In other
cases, the antigenic target is difﬁcult to predict on clinical grounds.
By comparison to VGKC-complex antibody determination, the
detection of LGI1 or CASPR2-reactivity offers very good speciﬁcity
for an antibody-mediated neurological syndrome, whereas low-
titre VGKC-complex antibodies (between 100 and 400 pM) were
Table 2
Summary of autoimmune epilepsy studies. Studies are derived from search criteria inmethods and details have been included only when theywere available in the article. MRI ﬁndings: increased T2/FLAIR signal in structures listed
within the table otherwise stated and studies showing multiple regions of brain involvement are further described in Supplementary Table 2. AEDs=Antiepileptic drugs; CPS=Complex partial seizures; CLN=Cortical laminar
necrosis; CI =Cognitive impairment; DN=Double negative VGKC-complex antibody (without LGI1 or CASPR2 reactivities); EPC=Epilepsia partialis continua; FBDS=Faciobrachial dystonic seizures; FS =Focal seizure; FS+ = Focal
seizure with impaired awareness; FM=Figural memory; FU=Follow-up; FLAIR= Fluid attenuated inversion recovery; GTC=Generalized tonic clonic seizures; GS=Generalized seizures; GAD=Glutamic acid decarboxylase;
GABA=Gamma amino butyric acid; IT= Immunotherapy; IGE= Idiopathic generalized epilepsy; IVIG= Intravenous immunoglobulins; IgG= Immunoglobulin G; MDZ=Midazolam; MMSE=Mini-mental state examination,
MTL=Medial temporal lobe; MTS=Mediotemporal sclerosis; MRI =Magnetic resonance imaging; mRS=Modiﬁed rankin score; N/A=Data not available; OCB=Oligoclonal bands; PCPC=Paediatric cerebral performance category
scale; PL =Pleocytosis; PLEX=Plasma exchange; PPF=Propofol; "Prot =Protein elevation; SGTCS=Secondary generalized tonic clonic seizure; SPS=Simple partial seizures; SE=Status epilepticus; SIADH=Syndrome of inappropriate
ADH secretion; SCLC=Small cell lung cancer; TLE=Temporal lobe epilepsy; TICS =Telephone interview of cognitive status (scored out of 41); VM=Verbal memory.
Author Type of study/
number of patients/
antibody type
Clinical
presentation
Types of seizure EEG MRI CSF AED given
before IT?
(Number/
duration)
Number of
AEDs used with
IT
IT used/outcome FU duration (range,
median)/drug side effects
a. LGI1/CASPR2/VGKC-complex antibody studies
Vincent et al.,
2004
Observational
n=1
0
Female =1
LGI1 (100%,
retrospective)
Amnesia, Seizures,
Confusion
GTC (n=3), FS
(n=3), GTC+CPS/
SPS (n=3)
Normal (n=2),
Diffuse
slowing+ focal
activity (n=4),
Focal activity
(n=2), Diffuse
slowing (n=1),
Focal
activity +diffuse
slowing (n=1)
Normal (n=2),
Unilateral MTL
(n=3), Bilateral
MTL (n=5)
OCB (n=5),
Mild PL
(n=5)
N/A N/A IT: n=10; steroids,
PLEX, IVIG Outcome:
Neuropsychology:
marked recovery
(n=6), slight recovery
(n=3), no recovery
(n=1)
2weeks–12months/N/A
Thieben et al.,
2004
Retrospective
n=7
Female =2
VGKC-complex
speciﬁcity
unknown
Seizures, Amnesia,
Irritability, Apathy
SPS (n=2), CPS
(n=5), GTC (n=2),
SE (n=1)
Epileptiform
discharges (n=4),
Mild bitemporal
slowing (n=1),
Diffuse/generalized
slowing (n=2)
Unilateral MTL
(n=1), Bilateral
MTL (n=6)
OCB (n=1),
"Prot (n=2)
N/A N/A IT: n=6; steroids. One
spontaneous recovery.
Outcome. TICS: Good
recovery (n=3;
TICS =34–35/41),
Partial recovery (n=3;
TICS =27-33/41),
Spontaneous (n=1;
TICS =36/41))
7–36months (median=24)
Mcknight et al.,
2005
Case control
n=16
Female =9
VGKC-complex
speciﬁcity
unknown
Amnesia, Seizures,
Depression
GTC (n=9), CPS
(n=7)
N/A Normal (n=9),
Hippocampal
(n=3), Claustrum
(n=1)
N/A N/A N/A IT: n=6; steroids and
IVIG. Outcome: Good
response (n=5), No
response (n=1)
2–60months (median=18)
Lai et al., 2010 Observational
n=57
Female =2
0 LGI1 (100%)
CASPR2 (2%)
Amnesia, Seizures Temporal lobe
seizures (n=42),
Myoclonus (n=18)
Epileptiform
discharge (n=4),
Diffuse or focal
slowing (n=11),
Seizures (n=11)
Temporal lobe
(n=43)
PL (n=8),
"Prot
(n=13)
N/A N/A IT: n=48; steroids,
PLEX, IVIG. Outcome:
Full recovery (n=12),
Moderate disability
(n=8), Mild disability
(n=27), Death (n=3).
Irani et al., 2011 Observationa
n=29
Female =10
LGI1 (88%)
CASPR2 (12%)
Double negative
(12%)
Amnesia,
Confusion,
Hallucinations,
Depression,
Dysautonomia,
Seizures
FBDS Normal (n=9),
Diffuse slowing
(n=9), Bilateral
frontotemporal
slowing (n=6),
Temporal sharp
waves (n=2)
Normal (n=12),
Unilateral MTL
(n=3), Bilateral
MTL (n=10)
Mild PL and
"Prot (n=5)
N/A 1–6
(median=2.6)
IT: n=27; steroids
PLEX, IVIG and
rituximab. Outcome:
Reduction in seizure
frequency >50%
(n=14), 20–50%
(n=12), <20% (n=1)
4years AEDs: Localized
rash (n=8), Erythroderma
(n=2), Steven Johnson
syndrome (n=2) IT: Steroid
induced psychosis (n=1);
infection (n=2)
Suleiman et al.,
2011
Case control
n=4
Female =3
Double negative
(100%)
Encephalopathy,
Fever, Behavioural,
Seizures
GTC (n=2), SE
(n=4), GS (n=2)
Generalized
slowing (n=2),
Focal slowing
(n=2), Epileptic
activity (n=1)
Normal (n=2), Left
parietal and
bifrontal (n=1),
Cerebral oedema
(n=1)
PL (n=4),
"Prot (n=2)
N/A N/A IT: steroids and IVIG.
Outcome: Good
recovery (n=1), TLE +CI
(n=1),
TLE+CI +psychiatric
(n=1), CI (n=1)
1–66months
(median=15.5)
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Table 2 (Continued )
Author Type of study/
number of patients/
antibody type
Clinical
presentation
Types of seizure EEG MRI CSF AED given
before IT?
(Number/
duration)
Number of
AEDs used with
IT
IT used/outcome FU duration (range,
median)/drug side effects
Quek et al.,
2012
Observational
n=32
Female =19
LGI1 (78%)
CASPR2 (6%)
Double negative
(17%)
Seizures,
Personality
changes, Anxiety/
Depression
SPS (n=27), CPS
(n=26), GTC
(n=17), EPC (n=3)
Epileptiform
discharge (n=20),
Focal slowing
(n=13),
Electrographic
seizures (n=15),
Generalized
slowing (n=12)
Normal (n=15),
Temporal/
extratemporal
(n=22)
Normal
(n=11), PL
(n=5),
"Prot
(n=17),
OCB (n=5)
>2 for
3weeks–
12years
(median=5)
>2 (median=3) IT: n=27; steroids,
PLEX. IVIG. Outcome:
Seizure freedom
(n=18), Seizure
improvement (n=4),
No change (n=5)
3–72months (median=17)
Shin et al., 2013 Observational
n=14
Female =6
LGI1 (100%)
Seizures, Cognitive
dysfunction,
Dysautonomia
FBDS (n=10), SE
(n=4)
Epileptiform
discharge (n=8),
Focal slowing
(n=2)
Unilateral MTL
(n=4), Bilateral
MTL (n=5)
Normal
(n=10),
"Prot
(n=3), PL
(n=1)
N/A N/A IT: n=14; steroids,
PLEX, IVIG, rituximab,
tacrolimus,
cyclophosphamide,
azathioprine.
Outcome: n=11 (mRS:
0–2), n=1 (mRS >2);
relapse (n=2)
1–24months
(median=4.5)
Toledano et al.,
2014
Observational
n=12
Female =5
LGI1 (92%)
CASPR2 (8%)
Seizures FS (n=6), FBDS
(n=4). FS+ (n=10).
GTC (n=7)
Normal (n=1),
Epileptiform
discharges (n=6),
Focal slowing
(n=2), Excessive
beta activity (n=1),
Temporal activity
(n=1),
Extratemporal
discharge (n=1)
Normal (n=2),
Bilateral MTL
(n=3), Right MTL
(n=1), Left MTL
(n=1), Right MTS
(n=1)
Normal
(n=5),
"Prot
(n=6), PL
(n=1)
>2 (median=3) >1 IT: n=12; steroids,
PLEX, IVIG,
mycophenolate
mofetil, azathioprine
Outcome: Seizure
freedom (n=10);
reduced frequency
(n=2)
2–86months With IT:
Steroid induced psychosis;
aseptic meningitis
Malter et al.,
2014
Retrospective
n=18
Female =6
LGI1 (50%)
CASPR2 (17%)
Double negative
(33%)
Amnesia,
Confusion,
Depression,
Seizures, Anxiety
FBDS (n=2) N/A Bilateral MTL
(n=12) Right MTL
(n=2) Left MTL
(n=5)
"Prot
(n=5), PL
(n=2)
N/A >1 IT: n=18; steroids,
mycophenolate mofetil
Outcome: Seizure free
(n=13); Persistent
seizures (n=5). No
deﬁcit in VM+FM
(n=6); Deﬁcit in
VM+FM (n=4); Deﬁcit
in FM (n=5); Deﬁcit in
VM (n=1)
5–70months (median=26)
Steroid-induced liver
failure (n=1)
Newey et al.,
2014
Observational
n=6
Female =3
VGKC-complex
speciﬁcity
unknown
Seizures, Altered
mental state,
Depression.
CPS (n=1) N/A Unilateral MTL
(n=2), Bilateral
MTL (n=1)
Normal
(n=3),
"Prot
(n=2), N/A
(n=1)
N/A >2 IT: n=5 (steroids, PLEX,
IVIG). Outcome:
Complete/partial
response (n=3)
N/A
b. NMDAR-antibody studies
Dalmau et al.,
2007
Observational
n=12
Female =12
Psychiatric
features, Seizures,
Movement
disorders,
Autonomic
instability, Reduced
level of
consciousness
GTC or CPS (n=11) Diffuse slowing
(n=7), Generalized
slowing/
epileptiform
activity (n=3)
Normal (n=3),
Bilateral MTL,
(n=3), Punctate
cortical
hyperintensites+/
meningeal
enhancement
(n=5)
PL (n=14),
OCB (n=3),
"Prot (n=7)
N/A >2 IT: steroids, PLEX, IVIG
(n=3); Tumour
resection (n=2); IT and
tumour resection
(n=7). Outcome: Full
recovery (n=8,
MMSE=28/30), partial
recovery (n=2,
MMSE=24/30), Death
(n=3)
7months–6years
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Table 2 (Continued )
Author Type of study/
number of patients/
antibody type
Clinical
presentation
Types of seizure EEG MRI CSF AED given
before IT?
(Number/
duration)
Number of
AEDs used with
IT
IT used/outcome FU duration (range,
median)/drug side effects
Dalmau et al.,
2008
Observational
n=100
Female=91
Psychiatric
features, Seizures,
Movement
disorders,
Dysautonomia,
Hypoventilation
GTC (n=45), CPS
(n=10), SE (n=6),
FS (n=7), SGTCS
(n=8), EPC (n=2),
Myoclonus (n=9)
Slow activity
(n=71), Epileptic
discharge (n=21)
MTL (n=22) PL (n=91),
"Prot
(n=32),
OCB
(n=26)
N/A N/A IT: n=92 (steroids,
PLEX, IVIG,
cyclophosphamide,
rituximab,
azathioprine); Tumour
resection (n=51).
Outcome: Full recovery
(n=47; mRS=0;
MMSE=29–30), Mild
stable deﬁcit (n=28
mRS=1–2; MMSE=25
–28) Severe deﬁcit
(n=18), Death (n=7)
1–194months
(median=17)
Iizuka et al.,
2008
Observational
n=4
Female=4
Psychiatric
symptoms,
Seizures,
Dyskinesia,
Hypoventilation
Convulsive seizure
(n=2), Tonic (n=1)
Diffuse delta
activity no
Paroxymal
discharge (n=3),
Irregular slowing
no paroxysmal
discharge (n=1)
Normal (n=3), MTL
(n=1)
PL (n=4),
OCB (n=1)
N/A >2 IT: n=2 (steroids, IVIG)
Outcome: Full recovery
(n=2); Gradual
recovery over 3–4years
(n=2)
4–7years
Niehusmann
et al., 2009
Prospective cohort
n=5
Female=5
Psychiatric
symptoms,
Extratemporal
epilepsy
Dyskinesia,
Dystonia,
Hypoventilation,
Reduced
consciousness
SGTC (n=2), CPS
(n=1), SPS +CPS
(n=1)
Focal slowing
(n=4), Generalized
slowing (n=1),
Epileptic activity
(n=3)
Normal (n=2),
White matter
(n=1) Cortex (n=1)
PL (n=5),
OCB (n=3)
2months N/A IT: n=3 (steroids, IVIG);
no treatment (n=2).
Outcome: None
relapsed on IT; 2 did
not relapse without IT
15–36months
(median=26)
Florance et al.,
2009
Observational
n=32
Female=26
Seizures,
Behavioural/
personality
changes,
Movement
disorders
FS/CPS (n=19), GTC
(n=2) SE (n=1), FS/
SE (n=1)
Epileptic activity
(n=7), Focal or
diffuse delta/theta
(n=22)
MTL,
periventricular and
cerebellar (n=5)
PL (n=27),
"Prot
(n=4), OCB
(n=5)
N/A >2 IT: n=30 (Steroids,
PLEX. IVIG, rituximab,
cyclophosphamide);
Tumour resection
(n=8);
Electroconvulsive
therapy (n=2).
Outcome: Full recovery
(n=9), Substantial
recovery (n=14),
Limited improvement
(n=8)
2–14.4months
(median=4.5)
Irani et al., 2010 Observational
n=44
Female=31
Seizures,
Confusion,
Psychiatric
symptoms,
Behavioural
changes,
Movement
disorders,
Dysautonomia
GTC (n=33) CPS
(n=16), SPS (n=12)
Epileptiform
discharge (n=22),
Generalized
slowing in delta or
theta range (n=35)
Normal (n=34),
Hippocampi (n=4)
or white matter
(n=6)
PL (n=30),
OCB
(n=23)
N/A N/A IT: n=35 (steroids,
PLEX, IVIG,
cyclophosphamide,
rituximab,
azathioprine,
mycophenolate
mofetil).Outcome: 75%
good recovery (mRS 0 –
2)
3.6–121months
(median=16)
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Table 2 (Continued )
Author Type of study/
number of patients/
antibody type
Clinical
presentation
Types of seizure EEG MRI CSF AED given
before IT?
(Number/
duration)
Number of
AEDs used with
IT
IT used/outcome FU duration (range,
median)/drug side effects
Armangue
et al., 2013
Observational
n=20
Female =14
Seizures,
Psychiatric
symptoms,
Movement
disorders
Seizures (n=12) Generalized
slowing (n=7),
Focal slowing
(n=3), Generalized
slowing/focal
activity (n=6).
Extreme delta
brush (n=1).
Epileptiform
discharge (n=1)
Temporal lobe
(n=6)
PL (n=14),
OCB (n=3),
"Prot (n=1)
N/A >2 IT: n=20 (steroids,
PLEX, IVIG, rituximab,
cyclophosphamide).
Outcome: Full
recovery (n=12,
PCPC=1 or 2), Mild
disability (n=5,
PCPC=1 or 2), Severe
disability (n=2,
PCPC=3 or 4), Death
(n=1)
4–149months
(median=17.5)
Titulaer et al.,
2013
Observational
n=577
Female =468
Seizures,
Psychiatric
symptoms,
Movement
disorders,
Behavioural
changes, Speech
problems,
Dysautonomia,
Reduction in
consciousness
Seizures (n=55) Slow pattern
(n=398), Epileptic
features (n=115)
Normal (n=360),
Abnormal (n=180),
Unknown (n=37)
Normal
(n=114), PL
(n=402),
"Prot
(n=93),
Unknown
(n=45)
N/A N/A IT: n=472 (steroids,
PLEX, IVIG, rituximab,
cyclophosphamide, and
tumour removal); no
treatment (n=29).
Outcome: Good in 1st
24months (n=394;
mRS=0–2), Good in
2nd 24months
(n=203; mRS=0–2),
Poor (n=29; mRS=3–
5), One or multiple
relapse (n=45)
4–186months
(median=24)
Viaccoz et al.,
2014
Observational
n=13
Seizures, Amnesia,
Dyskinesia,
Psychiatry,
Cognitive
FS (n=5). GTC
(n=3)
Normal (n=2),
Slow waves (n=4),
SE/seizure (n=6)
Normal (n=6),
Hippocampus
(n=4), Occipital
(n=1), Cerebellar
(n=1)
PL (n=10),
"Prot/OCB
(n=4)
N/A N/A IT: n=12 (steroids,
IVIG,
cyclophosphamide,
rituximab,
mycophenolate
mofetil). Outcome:
Favourable (n=10;
mRS=0–1), Complete
recovery (n=6;
mRS=0–1), Death
(n=1)
6–44months
(median=14)
Lim et al., 2014 Observational
n=40
Female =15
Seizures,
Psychiatric
symptoms,
Amnesia,
Dysautonomia,
Movement
disorders
Non- convulsive
status (n=6)
Epileptic discharge
(n=12),
Generalized or
predominantly
frontotemporal
slowing (n=10)
MTL (n=3) PL (n=15),
"Prot
(n=13)
N/A N/A IT: IT and/or tumour
resection (n=22); No
treatment (n=7).
Outcome: Favourable
outcome (n=14;
mRS=0–2); Poor
outcome (n=7;
mRS=3–6)
1–12months
(median=4)
c. GAD-antibody studies
Malter et al.,
2010
Observational
n=9
Females =7
Temporal lobe
Seizures
TLE (n=9) N/A Unilateral
hippocampal
atrophy (n=3),
Bilateral amygdalo-
hippocampal signal
(n=3)
OCB (n=5),
PL (n=2),
"Prot (n=2)
N/A 2 (1–5) IT: n=9 (steroids, IVIG,
cyclophosphamide).
Outcome: Abnormal
VM (n=5); Abnormal
FM (n=4). None seizure
free
18months
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Table 2 (Continued )
Author Type of study/
number of patients/
antibody type
Clinical
presentation
Types of seizure EEG MRI CSF AED given
before IT?
(Number/
duration)
Number of
AEDs used with
IT
IT used/outcome FU duration (range,
median)/drug side effects
Haberlandt
et al., 2011
Retrospective
n=4
Females =4
Amnesia,
Depression, Ataxia,
Seizures, Cognitive
decline
TLE (n=3). FS (n=1) N/A Unilateral MTL
(n=2), Bilateral
(n=1) MTL
OCB (n=2) N/A N/A IT: n=3 (steroids or
IVIG). Outcome:
Memory
impairment+TLE
(n=2), restitution
(n=1), memory
impairment+ epilepsy
(n=1)
13–67months
Lilleker et al.,
2014
Observational
n=6
Females =6
Seizures FS+GTCS (n=5), FS
(n=1)
Focal slowing,
sharp and slow
waves (n=6)
Normal (n=6) OCB (n=6),
"Prot (n=1)
2–4 over
9.5 years
>2 IT: n=5 (steroids, PLEX,
IVIG, azathioprine). Left
anterior temporal lobe
resection (n=1).
Outcome: No
improvement in
seizures (n=4);N/A
(n=1)
Optic neuritis (n=1);
Transverse myelitis (n=1);
Hepatotoxicity (n=1)
d. GABABR-antibody studies
Lancaster et al.,
2010
Observational
n=15 Female=7
Seizures, Amnesia,
Confusion,
Psychosis
CPS (n=2), FS
(n=2), GS(n=5),
GTC (n=2), SGTC
(n=1). SE (n=3)
Normal (n=1).
Temporal lobe
seizures,
Epileptiform
discharge or
temporal lobe
slowing (n=9).
Generalized
slowing (n=2)
Normal (n=4), MTL
(n=10), Corpus
callosum (n=1)
Normal
(n=1). PL
(n=8), OCB
(n=3)
N/A N/A IT: n=6 (steroid PLEX,
IVIG), Tumour
resection (n=3), No
treatment (n=4).
Outcome: Good
response to IT (n=6) or
IT+Tumour resection
(n=3), No clinical
improvement in
untreated patients
3–72months (median=10)
Boronat et al.,
2011
Observational
n=10
Female =1
Seizures,
Confusion,
Amnesia,
Disorientation,
Behavioural
changes
SE (n=1) N/A Normal (n=3).
Hippocampus and
amygdala (n=7)
PL (n=4) N/A N/A IT: n=7 (steroids and/
or IVIG), Chemotherapy
(n=4). Outcome:
Complete recovery
(n=3), Partial response
(n=4), No response
(n=3)
N/A
Hoftberger
et al., 2013
Observational
n=20
Female =8
Seizures, Amnesia,
Confusion,
Hallucinations,
Cerebellar ataxia,
Opsoclonus
myoclonus
Seizures (n=17), SE
(n=1)
Normal (n=5).
Epileptic activity
with or without
generalized
slowing (n=7)
Normal (n=7),
Unilateral or
bilateral MTL
(n=9), Pial
enhancement
(n=1)
PL (n=6),
"Prot
(n=1), PL/
"Prot (n=7)
N/A N/A IT: n=19 (steroids,
PLEX, IVIG, rituximab,
cyclophosphamide or,
mycophenolate
mofetil),
Chemotherapy (n=4),
No treatment (n=3).
Outcome: Complete
recovery (n=7), Partial
recovery (n=8)
0.75-45months
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Table 2 (Continued )
Author Type of study/
number of patients/
antibody type
Clinical
presentation
Types of seizure EEG MRI CSF AED given
before IT?
(Number/
duration)
Number of
AEDs used with
IT
IT used/outcome FU duration (range,
median)/drug side effects
Dogan
Onugoren
et al., 2014
Retrospective
n=10
Female =2
Amnesia,
Confusion, Apraxia,
Aphasia, Catatonia,
Cerebellar
dysfunction
GTC (n=9), SE
(n=2)
Generalized or
focal slowing(n=6),
Epileptic activity
without slowing
(n=2), Epileptic
activity with focal
or generalized
slowing (n=2)
Normal (n=1),
Unilateral MTL
(n=6), Bilateral
MTL (n=3), CLN
(n=3)
PL (n=6),
OCB (n=7)
N/A N/A IT: n=8 (Steroids, PLEX,
IVIG, rituximab,
cyclophosphamide,
azathioprine),
Chemotherapy (n=4),
Radiotherapy (n=1).
Outcome: Full recovery
(n=1), Slight recovery
(n=1), Decline in
cognitive function
(n=5), Death (n=3)
2–9months
e. AMPAR-antibodies studies
Lai et al., 2009 Observational
n=10
Female =9
Amnesia,
Confusion,
Behavioural
changes,
Disorientation,
Seizures
FS (n=1), GTC
(n=2)
Normal (n=2),
Slow activity
(n=2), Sharp waves
(n=2), Theta
activity (n=1),
Epileptic activity
(n=1)
Normal (n=1), MTL
(n=8), Changes in
the anterior septal
nuclei (n=2)
OCB (n=3),
PL (n=9),
"Prot (n=7)
N/A N/A IT: n=9 (steroids, PLEX,
IVIG, azathioprine),
Tumour resection+ IT
(n=6). Outcome: Good
recovery (n=9),
Relapses (n=5), Death
(n=1)
8–50months
(median=16)
Graus et al.,
2010
Retrospective
n=4
Female =4
Confusion,
Agitation,
Personality
changes, Aphasia,
No seizures
N/A Diffuse slowing
with occasional
sharp waves over
the frontal region
(n=1), Episodic
slow waves in
frontal region
(n=1)
Normal (n=2) Normal
(n=2)
N/A N/A IT: n=2 (steroids).
Outcome: Full
recovery (n=2)
N/A
Dogan
Onugoren
et al., 2014
Retrospective
n=3
Female =1
Amnesia,
Psychiatric
symptoms, No
seizures
N/A Normal (n=3) Bilateral MTL
(n=3), CLN (n=2)
PL (n=1) N/A N/A IT: n=2 (steroids, PLEX,
IVIG, azathioprine,
rituximab),
IT + chemotherapy
(n=1). Outcome: Good
recovery (n=2), Mild
recovery (n=1)
5–14months
Hoftberger
et al., 2015
Retrospective
n=22
Female =14
Amnesia,
Confusion,
Insomnia, Seizures
SE (n=1) Normal (n=4)
Epileptiform
activity (n=4) Focal
activity (n=5)
Generalized
activity (n=5) Slow
activity (n=1)
Lateralized periodic
slowing (n=1)
Normal (n=4),
Unilateral MTL
(n=2), Bilateral
MTL (n=9)
Normal
(n=6), PL
(n=11),
"Prot
(n=10)
N/A N/A IT: n=25 (steroids,
PLEX, IVIG, rituximab,
cyclophosphamide),
Tumour resection
(n=7), Chemotherapy
(n=8), Radiotherapy
(n=6). Outcome: Good
response (n=5, mRS
score, 0–1), Partial
response (n=10, mRS
score, 2–3), Poor
response (n=6)
5–266weeks
(median=72)
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O.D. Bakpa et al. / Seizure 41 (2016) 26–4134noted in an elderly stroke cohort at a frequency of around 6%, rates
of LGI1- and CASPR2-antibodies are much lower in controls [7,14–
18]. Therefore, we preferentially use the terms LGI1- and CASPR2-
antibodies below. The remaining VGKC-complex antibodies
without LGI1 and CASPR2 reactivities are termed ‘double-negative’
and their clinical signiﬁcance is less clear. We reserve the term
‘VGKC-complex antibodies’ when LGI1 and CASPR2-antibody
assays were not performed (often prior to 2010).
Patients with LGI1-antibodies are often males (65%), older than
50 years, and present with features of acute or subacute amnesia,
confusion, sleep disturbances, and both frequent FBDS and medial
temporal lobe seizures. In under 10% of cases, the condition is
found to be paraneoplastic, usually associated with thymoma, or
more rarely small cell lung cancer (SCLC) [7,14,19]. In around 60%
of cases with LGI1-antibodies, unilateral/bilateral hippocampal
high signal is found in the mesial temporal lobe on magnetic
resonance imaging (MRI), consistent with limbic encephalitis (LE)
[7,14,20]. This is usually localized to the hippocampus and
amygdala, occasionally straying into the insula cortex or para-
hippocampal gyrus. In addition, there have been more recent
reports of basal ganglia and hypothalamic involvement in MRI
studies of such patients [21–23]. However, around 40% of patients
show no imaging abnormalities and therefore clinical recognition
remains paramount. The VGKC-complex/LGI1-antibody serum
concentration is raised compared to that in the CSF at disease
onset [7,14,20] and in a few cases with well-deﬁned syndromes
(such as FBDS) LGI1-antibodies are undetectable in CSF (Irani,
unpublished observations) [24]. Typical encephalitic CSF ﬁndings,
such as lymphocytic pleocytosis, oligoclonal bands (OCBs) and
elevated protein, are uncommon: routine CSF analysis is normal in
around 60% of patients [7,20]. Other characteristic ﬁndings include
serum hyponatremia, often caused by syndrome of inappropriate
ADH secretion (SIADH) [7], and abnormal electroencephalogram
(EEG) appearances with temporal spike waves and frontotemporal
slowing [14,25,26].
Over 70% of seizures reported in studies were of focal onset with
secondary generalization [7,19,23,27,28], however in some gener-
alized tonic-clonic seizures a focal onset was not apparent [7,28–
30]. The characteristic semiology termed FBDS has been described
in patients with LGI1-antibodies and will be discussed below
[22,31]. In addition, seizures with prominent bradycardia and
piloerection appear more suggestive of a LGI1-antibody-associated
syndrome [32,33].
More unexpected manifestations have also been reported with
these antibodies. For example, VGKC-complex antibodies (often
CASPR2-antibodies) have been associated with chronic, often
analgesia-refractory, pain. However, only 2% of patients in this
study had seizures, suggesting some non-epileptogenic pheno-
types are associated with these antibodies [34]. This is also true for
others patients with double-negative VGKC-complex antibodies
[14,16,18]. Indeed, perhaps consistent with a lack of seizures in
this cohort, the pathogenic relevance of double-negative anti-
bodies remains uncertain [11,35]. Therefore, LGI1- and CASPR2-
antibodies are of much greater relevance to epileptologists.
4.2. Faciobrachial dystonic seizures (FBDS)
FBDS represent a distinctive seizure semiology which were ﬁrst
reported in three patients [31] and subsequently the term was
coined after observation of 26 additional cases [22]. Following
these initial descriptions, multiple cases have been recognized and
reported worldwide [26,36–40]. FBDS are characterized by brief
episodes (usually <3 s) of synchronous dystonic arm posturing and
ipsilateral facial grimacing occurring at a median of 50 times per
day. Some patients can also develop longer episodes and
prominent leg involvement. A clinically important link between
Table 3
Clinicoradiological characteristics of VGKC-complex, NMDA, GAD and AMPA antibody associated encephalitis. AED = Antiepileptic drugs; AMPAR = Alpha-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid receptor; CSF = Cerebrospinal ﬂuid; CASPR2 = Contactin-associated protein2; CV2/CRAMP5 = Collapsin response mediator protein;
CPS = Complex partial seizure; EEG = Electroencephalogram; FBDS = Faciobrachial dystonic seizures; GTC = Generalized tonic clonic; GABA = Gamma aminobutyric acid;
GlyR = Glycine receptor; GluR = Glutamate receptor; GAD = Glutamic acid decarboxylase; LGI1 = Leucine-rich glioma inactivated1; MRI = Magnetic resonance imaging;
MTL = Medial temporal lobe; NMDAR = N-methyl-D-aspartate; OCB = Oligoclonal bands; SE = Status epilepticus; SOX1 = Sex determining region Y-box 1; SPS = Stiff Person
Syndrome; SCLC = Small cell lung cancer; T1DM = Type 1 diabetes; VGCC = Voltage gated calcium channel.
Characteristic
features
LGI1>CASPR2
(VGKC-complex)
NMDAR GAD GABABR AMPAR
Gender M>F F>M F>M M>F F>M
Typical age group >50 years <40 years >20 years > 40 years > 40 years
Neurological
features
Memory loss
Confusion
Temporal lobe
seizures
FBDS
Multistage encephalopathy
with: Psychiatric
symptoms
Extratemporal seizures
Movement disorders
Autonomic instability
Coma
Memory loss
Temporal lobe seizures
Coexisting
autoimmune disorders
including T1DM, SPS
Memory loss
Seizures
Confusion
Amnesia
Seizures
Insomnia
Confusion
Psychiatric
Features
Psychosis
Personality
changes
Depression
Anxiety
Psychosis
Behavioural disturbances
Delusions
Agitation
Depression
Anxiety
Psychosis
Hallucination
Behavioural changes
Psychosis
Confabulation
Agitation
Personality changes
Characteristic
seizures
FBDS
CPS
GTC
GTC
SE
CPS
GTC
CPS
CPS
GTC
SE
Focal motor
GTC
CPS
Tumour association Thymoma
SCLC
Ovarian teratoma SCLC SCLC Thymoma
SCLC
Target antigen LGI1 & CASPR2 NR1 subunit GAD-65 GABABR GluR1/2
MRI High signal change
in MTL, less
commonly basal
ganglia
Normal although non-
speciﬁc signal changes in
medial temporal structures
Normal, although
increased signal in MTL
Increased signal in MTL Increased signal in MTL
EEG Focal or
generalized
slowing
Extreme delta brush, focal
or diffuse delta/theta
activity
Focal or generalized
slowing
Focal or generalized
epileptic activity
Focal epileptic activity
Treatment &
outcome
Good response to
immunotherapy
Responds slowly to
immunotherapy
Poor treatment
outcome with
immunotherapy and
AEDs
Good response to
immunotherapy
Relapses are common
although there is good
response to
immunotherapy
O.D. Bakpa et al. / Seizure 41 (2016) 26–41 35FBDS and development of cognitive impairment (CI) has been
observed: around 70% of patients developed CI a median of 35 days
following the onset of FBDS, while another 20% developed FBDS
after the onset of CI. Interestingly, around 10% of patients with
FBDS, who received IT and antiepileptic drugs (AEDs), never
progressed to develop CI [22]. In a prospective study of ten patients
with FBDS, eight of ten patients who received AEDs or no treatment
developed CI. By contrast, the two patients who received IT did not
develop CI [41]. Overall, AEDs were only effective in about 10% of
patients, and frequently resulted in severe cutaneous reactions. By
contrast, FBDS typically respond to IT with corticosteroids and
sometimes plasma exchange (PLEX) [22,41]. In another study
involving 14 patients with LGI1-antibodies, at 1 month follow-up a
superior response was observed in patients treated with cortico-
steroids and IVIG, in contrast to those who only received
corticosteroid treatment [26].
4.3. NMDAR-antibody associated encephalitis
NMDAR-antibody associated encephalitis is a recently
described disorder in which infrequent seizures are associated
with the presence of autoantibodies directed against the
extracellular domain of the NR1 subunit of the NMDAR.
Table 2b focuses on the clinical and electrographic-features of
relevant studies. NMDAR-antibody associated encephalitis is
associated with a characteristic set of clinical features which
were ﬁrst reported in 12 young women who all had a diffuse
encephalopathy with seizures and psychiatric symptoms in
association with teratomas (ovarian n = 11, mediastinal n = 1)[2]. Importantly, patients showed signiﬁcant improvements
following tumour removal and IT. Subsequently, it has been
recognized that the disease can affect both males and females,
and that it is non-paraneoplastic in around 70% of cases,
especially younger children [3,42–46].
The clinical features associated with NMDAR-antibodies often
evolve in stages [3,47,48]. The syndrome typically begins with
prodromal low-grade fever, with headache and fatigue unrelated
to a known infectious aetiology. The subsequent phase is
characterized by delusions, hallucinations (visual or auditory)
and personality change in addition to speech difﬁculties,
disorientation and seizures. In a study of 100 patients, seizures
were reported in 76, with generalized tonic clonic seizures (GTCS;
n = 45), complex partial seizures (CPS; n = 10), secondary gener-
alized seizures (n = 8), refractory status epilepticus (n = 6), focal
motor seizures (n = 7) and epilepsia partialis continua (n = 2) [43].
Following a lag of 10–20 days, patients typically progress to a
phase with abnormal movements (such as orofacial dyskinesia
and choreoathetoid movements), reduction in consciousness and
ﬂorid dysautonomia, often necessitating intensive care admission
[3,48]. Although the characteristic movements of the hyperkinetic
phase are carefully described [49], they have been confused with
seizures [48] despite scalp EEGs usually demonstrating no seizure
activity. However, both clinical and electrographically-deter-
mined seizures and a movement disorder can sequentially appear
in a single limb within an individual patient over seconds,
suggesting a set of common neuronal networks which may be
differentially engaged to generate the relative cortical versus
subcortical activity [50].
O.D. Bakpa et al. / Seizure 41 (2016) 26–4136In addition, NMDAR-antibodies have been identiﬁed in patients
with new-onset epilepsies. Niehusmann and colleagues reported
NMDAR-antibodies in 5 of 19 women (age range 15–45 years). All
patients had extratemporal epilepsy which was often, but not
always, associated with neuropsychiatric symptoms, reduced level
of consciousness and speech disturbance. Other features included
nystagmus, dyskinesia, dystonia and hypoventilation. All patients
were started on AEDs in the ﬁrst 2 months of seizure onset. At
median follow up of 26 months, seizure relapse was seen in two
patients on AEDs. Clinical improvements in seizure frequency were
seen in three patients treated with IT comprising of corticosteroids
and IVIG.
Imaging has a limited role in a positive diagnosis of NMDAR-
antibody encephalitis as MRI and CT ﬁndings are often normal or
non-speciﬁc, despite the presence of multifocal neurological
dysfunction [3,43]. Indeed, non-speciﬁc changes involving the
medial temporal lobe, basal ganglia, periventricular or subcortical
areas, pons and cerebellar cortex may be seen in about 20% of cases
[2,51,52]. However, recent studies indicate abnormal resting state
and diffusion tensor imaging [53], and that NMDAR-antibody
encephalitis may occur simultaneously with clinical and MRI
features suggestive of demyelinating disorders [54,55]. A distinc-
tive EEG ﬁnding in NMDAR-antibody encephalitis is a generalized
slow delta wave with a rhythmic fast beta wave; this pattern is
described as the extreme delta brush because of its similarity with
waveforms seen in premature infants [56].
The serum and CSF should both be examined because while
NMDAR-antibody titres are consistently around 10 times higher in
the serum than CSF, the lower total immunoglobulin G (IgG)
concentration in CSF appears to offer a better signal to noise ratio in
the immunoﬂourescent assay [3,57,58]. Also, CSF shows early
lymphocytic pleocytosis in 80% of cases, and a later presence of
OCBs (60% of cases) [3,43].
Other than the presence of a NMDAR-expressing ovarian
tumour, likely to be an immunizing factor, causes of NMDAR-
antibody generation have remained obscure. However, recent
studies have demonstrated the association of herpes simplex virus
encephalitis (HSVE) with NMDAR-antibodies [9,59,60]. In a
retrospective study of patients with HSVE, serum and CSF
NMDAR-antibodies were detected in 13 of 44 cases both early
and late after HSVE [60]. In addition, days to weeks after HSVE,
relapses of encephalopathy with choreoathetosis have been
associated with de novo generation of NMDAR-antibodies, and
provide another mechanism for NMDAR-antibody generation
[9,59]. Other recent studies have shown Creutzfeldt-Jakob disease
[61] and Varicella-Zoster virus encephalitis as potential triggers of
NMDAR-antibodies [62], and collectively suggest a group of
illnesses which may trigger antibody-mediated epilepsies.
4.4. GAD-antibody associated encephalitis
Glutamic acid decarboxylase (GAD) is an intracellular enzyme
that catalyses the conversion of L-glutamic acid to gamma-
aminobutyric acid (GABA). GAD is expressed in GABAergic neurons
and pancreatic b-cells. Antibodies to GAD are associated with
several autoimmune disorders including type 1 diabetes mellitus
[63], Stiff Person Syndrome (SPS) [64], and cerebellar ataxia [65].
Recently, high titres of GAD-antibodies were recognized in a
subgroup of patients with non-paraneoplastic LE (Table 2c). In a
study involving 53 patients with LE, nine had elevated levels of
GAD-antibodies of which seven were females who presented
predominantly with temporal lobe seizures. The epileptic seizures
were refractory to both AEDs and IT, by contrast to seizures
associated with LGI1-antibodies [66]. MRI ﬁndings in most studies
show unilateral or bilateral mesiotemporal high signal on T2/
FLAIR, consistent with the characteristic presentation of memorydisturbance and temporal lobe epilepsy seen in these patients [67].
This appearance, as with other causes of LE, may evolve to atrophy
and hippocampal sclerosis. The CSF analysis typically shows the
presence of OCBs, lymphocytic pleocytosis, elevated protein and
intrathecal synthesis of GAD-antibodies [68]. Recently, GAD-
antibodies, especially in elderly male patients, have been shown to
more commonly suggest an increased risk of an underlying tumour
[69] and as a non-paraneoplastic syndrome in children [70].
4.5. Gamma aminobutyric acid (B) receptor (GABABR) antibody
associated encephalitis
GABABRs are critical inhibitory neuronal receptors. Antibody-
mediated disruption of these receptors has been linked with
seizures and changes in memory and behaviour (studies summa-
rized in Table 2d). In an observational study involving 15 patients
with GABABR-antibodies and LE (median age 62 years, range 24–
75 years), all presented with seizures, confusion and memory
dysfunction. Seizures were the predominant presenting feature in
13, and were mostly of temporal lobe onset with secondary
generalization. Two patients presented with status epilepticus.
Seven patients had tumours, of which ﬁve had SCLC. CSF ﬁndings
showed lymphocytic pleocytosis (n = 4) and MRI showed increased
signal, typical of LE. Clinical improvement was seen in six patients
who received IT alone and three who had IT and tumour removal.
There was no clinical improvement in four patients without IT [5].
In another study, GABAB receptor-antibodies were identiﬁed in
ten patients with similar demographics, prominent seizures and
frequent SCLC. Only two patients made a complete recovery, four
had partial responses and three had no response [71]. Separately,
antibodies to GABAB receptors were identiﬁed in 10 patients
(median age 70 years); ﬁve had SCLC. MRI showed bilateral
mediotemporal (n = 9) and cortical (n = 2) abnormalities. EEG
demonstrated encephalopathy, partly with epileptiform dis-
charges. Five patients received IT, two had tumour treatment,
and three both therapies. One patient recovered fully, one
improved slightly, ﬁve experienced cognitive decline and three
died [72]. Another study conﬁrmed many of these ﬁndings and
added ataxia, opsoclonus and status epilepticus to the LE syndrome
[73].
4.6. a-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptor (AMPAR)-antibody associated encephalitis
Antibodies to the AMPAR have recently been described in
patients with LE. Not only are AMPAR-antibodies the least frequent
of these antibodies (Waters and Irani, unpublished) but Table 2e
suggests they are also the least epileptogenic. In an observational
study involving ten patients with AMPAR-antibodies (age range
38–87, median age 60) and LE who presented with confusion,
amnesia and disorientation, seven patients had tumours (lung
(n = 2) breast (n = 2) and thymus (n = 3)) and only four patients had
focal seizures (n = 2) or GTCS (n = 2). Nine patients were treated
with IT (IVIG, corticosteroids, PLEX and azathioprine), and six
patients underwent tumour resection. All nine patients had good
responses to IT and ﬁve patients had relapses at 2–101 months
after the initial episode of encephalitis [4]. In other studies,
AMPAR-antibodies were detected in three patients presenting
with amnestic disturbances [72], and in others presenting with
psychosis [74]. Recent series prove this disorder is commonly
paraneoplastic [75,76].
5. Autoantibodies in patients with chronic refractory epilepsy
The autoantibodies associated with autoimmune encephalopa-
thies, discussed above, have also been detected in unselected
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McKnight et al. reported the presence of VGKC-complex and GAD-
antibodies in 67 patients presenting with drug resistant epilepsy
[28]. The group with VGKC-complex antibodies was derived from a
cohort selected due to a high clinical suspicion of autoimmunity,
and consisted of 16 patients; eight presented with a short duration
(1–16 weeks) of seizures. Patients with a short duration of epilepsy
often had higher titres of VGKC-complex antibodies and ﬁve of
these six patients were treated with IT (oral corticosteroids, PLEX
and IVIG) and made a good recovery. In contrast, all ﬁve GAD-
antibody positive patients were females with long durations of
refractory epilepsy with onset in childhood or early teens, and a
poorer IT response. In a subsequent study involving 106 patients
(all females) with chronic refractory epilepsy, voltage gated
calcium channel (VGCC) antibodies (>45 pM) were slightly raised
in one patient, GAD antibodies were absent (<3 U/ml) in all
patients, and six patients had raised VGKC-complex antibody titres
(118–1406 pM, normal range <100 pM). Seizures were mainly
GTCS, tonic or atonic with childhood onset, and MRIs were normal
in the six patients with VGKC-complex antibodies [77]. In a
retrospective study of patients with refractory epilepsy and a
suspected autoimmune aetiology, 18 of 32 had VGKC-complex
antibodies, seven had GAD65-antibodies, and one patient had
NMDAR-antibodies. Other antibodies identiﬁed included collapsin
response mediator protein-5 (CRMP-5; n = 2), Ma2 (n = 1), and
ganglionic acetylcholine receptors (n = 1). In this study, 81% of
patients improved clinically after IT, with 67% achieving seizure
freedom within a period of 10 months [29]. Overall, the patients
with autoantibodies often had frequent, AED-refractory seizures
with neuropsychiatric comorbidities. Interestingly, these features
overlap with the autoimmune epilepsies described above, and
suggest common themes in the phenotype of autoimmune
epilepsies, and perhaps a rationale to select patients for antibody
testing.
In another study of 29 patients with autoimmune epilepsy, 18
responded positively to a trial of IT (iv methylprednisolone 1,000 mg
or IVIG 0.4 g/kg daily for 3–5 days, followed by once weekly
infusions of iv methylprednisolone or IVIG for 6–12 weeks at the
same dose). Ten patients became seizure free, the others had more
than 50% reduction in seizures following treatment. 43% of patients
who failed to respond to ﬁrst-line agents (iv methylprednisolone or
IVIG) improved following treatment with second-line agents such as
rituximab [78]. Therefore, several studies suggest the presence of
autoantibodies with pathogenic potential in the serum of patients
with epilepsies. In those patients with a more abrupt onset of
seizures, multiple studies provide consistent observational evidence
to suggest a preferential response to IT over AEDs.
However, the results of these studies cannot yet readily be
generalized to the wider population of patients with epilepsy for
several reasons. Firstly, none of these studies have consistently
measured the presence of autoantibodies in the CSF. This has been
a requisite of some studies [57] and intuitively suggests a greater
likelihood of pathogenicity. However, it is not known whether
serum NSAbs alone have sufﬁcient CNS-pathogenicity without
accompanying detectable CSF antibodies, nor is the pathogenic
necessity of intrathecal antibody synthesis well understood.
Animal models suggest that antibodies can cross the blood brain
barrier, and we know some patients with classical FBDS and serum
LGI1-antibodies do not have CSF LGI1-antibodies. In these patients,
there is little doubt that such a distinctive clinical syndrome is
related to the presence of LGI1-antibodies which are detectable in
serum only. By extension, the presence of serum LGI1 or CASPR2-
antibodies in unselected patients with epilepsy of unknown
aetiology may be sufﬁcient evidence to prompt ITs, and in two
studies this approach was employed with some beneﬁts [79,80].
While the relative roles of CSF and serum remain incompletelyunderstood, we recommend testing of both CSF and serum in all
patients when possible, as these cumulative data will give
clinicians the best opportunity to understand and monitor the
patient’s disease. Secondly, no study has prospectively evaluated
the frequency of autoantibodies in unselected patients with a ﬁrst
adult-onset seizure to determine their wider relevance. An
increased autoantibody frequency in patients with acute versus
more chronic forms of epilepsy, would perhaps suggest the acute
onset cases derive the most beneﬁt from IT. Thirdly, sequential
results of seizure frequency and antibody-levels need to be
determined in several individual patients over time. Such
correlations can be very close in patients with LGI1-antibodies
and FBDS, but seizures can also often stop before antibody levels
fall markedly [22,41,80]. Finally, it is currently unclear whether a
substantial number of epilepsy patients without encephalopathic
features respond well to ITs. Certainly, patients with FBDS usually
do. However, other cohorts demonstrating a good IT response
included patients with frequent MRI and cognitive changes,
suggesting these patients may have been classiﬁed with an
autoimmune encephalopathy rather than a pure antibody-
associated epilepsy [78].
All of these questions return to the important issue of ITs. Of
course, an IT response is of great potential interest to epileptol-
ogists, as around 30% of patients with epilepsy are currently AED-
refractory. Also, paradigms already exist for efﬁcacy of ITs in
epilepsies: for example, corticosteroids and PLEX are advocated in
the treatment of refractory status epilepticus [79–81]. However, to
be certain of efﬁcacy, a randomized clinical trial is required. In the
interim, immunosuppressive therapy could be reserved for
patients with NSAbs, and either AED-refractory seizures or
explosive onset of seizures, particularly in the context of associated
neuropsychiatric features.
6. Treatment and outcomes in antibody-associated epilepsies
The striking differences in the clinical presentation between the
various NSAb-associated epilepsies suggest that a ‘‘one size ﬁts all’’
approach to treatment would not be appropriate. Treatments must
be tailored to the individual. The paragraphs below summarize the
most commonly pursued treatment strategies, and available
observational evidence. There are no standard protocols regarding
the particular ITs which are most appropriate for the different
forms of NSAb-mediated disorders. Fig. 1 summarizes a proposed
treatment regimen for patients with encephalopathic or acute
onset of autoimmune epilepsy. Certainly, patients with CSF and
serum autoantibodies who are severely ill should be given rapid
escalation of ITs. Similarly, patients with a syndrome that is
consistent with an autoimmune aetiology, regardless of autoanti-
body status, are also obvious candidates for ITs. The debate is less
clear-cut around patients with few features of autoimmune
epilepsy (such as infrequent, typical temporal lobe seizures plus
no neuropsychiatric features) and serum-only autoantibodies. In
these patients, a staged approach seems reasonable, whereby
perhaps only AED-refractory patients receive a predeﬁned course
of ITs with accurate baseline and post-treatment measurements of
seizure frequency. However, the administration of ITs – in terms of
number of therapies, doses and durations – often depends on the
antibody in question. Therefore, the IT regimes discussed below are
considered in the context of the antigenic target. Importantly,
assuming limited reporting bias, Table 2 suggests a low rate of
side-effects from ITs, not different to AED-induced side effects.
6.1. LGI1- and CASPR2-antibody associated encephalopathy
Studies describing the treatment of LGI1-antibody associated
encephalopathy are summarized in Supplementary Table 1A. Some
Benefit      
Benefit      
Limited  or no 
benefit
Limited  or no 
benefit at 1-2  weeks  
Opti ons inc lude : 
• Long term 
predn iso lone 
taper ; 
• Regular IVMP 
infus ion s +/ -
steroid sp aring 
agen ts e.g
mycoph ena late
• No furthe r 
treatmen t(s)
• AEDs
• Seda tives 
and an ti-
psycho tics 
• Intubation
• Mo vemen t 
diso rde r 
drugs
All  pa tien ts 
receive 
approp riate 
symptomatic 
the rapy
Diagnosis of Autoimmune ep ilep sy:
Clini cal
CSF an d serum
• Ritux imab  e. g. 1g twice over 2  weeks
• Cyclophosphamide  (e. g. 500mg IV fortnightly for 4  mon ths)
Limited  or no 
benefit
Conside r more  experi men tal drugs su ch as 
bortezomib,  alemtuzumab , or intrathecal
metho trex ate/ritux imab  or employ supportive 
car e awa iti ng a d elayed  rep sonse
• IV Methylpredn isolon e 1g 
daily for 3-5 da ys.  
• +/- Pr edn iso lon e 60 mg da ily 
for 2 weeks     
• IVIG 2g/kg over 5 da ys 
• PLEX for 5-7 da ys
Fig. 1. Immunotherapy escalation options in acute onset/encephalopathic autoimmune epilepsy. The time period to wait before determining whether treatment is successful,
or of limited or no beneﬁt, is unclear. Likewise, there are currently no agreed criteria on what degree of improvement is deemed satisfactory beneﬁt.
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steroids, IVIG and PLEX for patients with autoantibodies to LGI1
and CASPR2 [7,11,26,82]. In a retrospective study of ten patients
with high titres of VGKC-complex antibodies who presented
with seizures and memory disturbance, IT (including IVIG 2 g/
kg/day, 100 mg prednisolone on alternate days and PLEX for
5 days) resulted in signiﬁcant clinical improvement in frequency
of seizures and cognition in six patients within 2 weeks–
12 months, correlating with reductions in antibody titres [7].
Earlier ITs, and possibly corticosteroids, appeared to provide
greater beneﬁts.
In another retrospective study of nine patients with VGKC-
complex antibodies and LE, the IT regimen consisted of PLEX
(50 ml/kg), IVIG (2 g/kg) and iv methylprednisolone (1 g thrice)
followed by a maintenance dose of oral prednisolone (starting at
1 mg/kg/day). Signiﬁcant clinical improvements were observed, asseizures stopped in all nine patients within 1 week of treatment
and cognitive functions improved in all patients within 3 months.
VGKC-complex antibody titres returned to normal within 1–
4 months [82]. In agreement with these seizure-related observa-
tions, despite a typically poor response to AEDs, FBDS are often
exquisitely sensitive to corticosteroids and PLEX. A small
prospective study has suggested termination of FBDS may be
achieved very rapidly (often within days – few weeks) with these
agents, and that cessation of FBDS may be associated with a
prevention of cognitive impairment [41].
Of 14 patients with LGI1-antibodies (median age 60.5 years,
range 41–78), all presented with seizures (ten with FBDS, four with
status epilepticus) and twelve showed changes in memory and
behaviour. Seven patients were treated with corticosteroids only:
all seven showed clinical improvement. Further improvements
were seen following administration of IVIG. Five patients received
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four of these achieved seizure freedom without relapse. The ﬁve
patients in this case series who received IT within 1 month of
symptom onset showed the greatest improvement in seizure
frequencies [26].
IT with rituximab has been reported to have beneﬁcial effects
in only few patients with LGI1-antibodies. Only one of seven
patients who received rituximab showed a clear clinical
improvement, and beneﬁts were more equivocal in three others
[39,83]. However, while patients with LGI1-antibodies appear to
improve markedly in the shorter-term with IT [7,14,34], the
modiﬁed Rankin Scale outcomes at 4 years do not appear to
differ between groups treated with steroids plus IVIG and/or
PLEX, or steroids alone [11]. Furthermore, these retrospective
observational ﬁndings should be taken in the context of a few
reports showing similar improvements in patients without ITs
[84]. This is in concordance with the observation that most of
these patients relapse infrequently and make good improve-
ments with steroids alone.
6.2. NMDAR-antibody associated encephalitis
Patients with NMDAR-antibody associated encephalitis often
pose signiﬁcant therapeutic challenges, principally related to the
long natural history of the disease and its tendency to frequent
relapses [3,43]. The available treatment data for NMDAR-antibody
associated encephalitis are summarized in Supplementary Table
1B. In a study involving 100 patients, 92 received ITs with
corticosteroids (n = 76), IVIG (n = 62) or PLEX (n = 34) and 51
patients underwent tumour resection. At median follow up of
17 months (range 1–194), 47 had made a full recovery, 28 had a
mild stable deﬁcit, 18 had severe deﬁcits and 7 died. At a median of
18 months, relapses were seen in 15 of the 100 patients [43]. In
another study, patients with non-paraneoplastic NMDAR-antibody
encephalitis recovered faster if commenced on IT less than 40 days
after symptoms onset [3], and relapses were noted in 10 of 35
(29%) patients who often received a short duration of ITs [3]. In the
largest observational study of 577 patients, 472 patients (94%)
received ﬁrst line IT (IVIG, PLEX and steroids) or tumour removal
(found in 38%), with 53% experiencing clinical improvements
within 4 weeks. In the group of 221 patients without clinical
beneﬁts from ﬁrst-line IT, second-line IT (rituximab and cyclo-
phosphamide) was instituted in 57% with better clinical outcomes
reported in these patients compared to those who did not receive
second line treatments. Those receiving second line ITs also had
fewer relapses [45]. In summary, observational data suggest early
and escalating ITs show efﬁcacy in patients with NMDAR-antibody
encephalitis.
6.3. GAD-antibody associated encephalitis
GAD-antibody associated disorders often show a disappoint-
ing clinical response to ITs despite aggressive approaches and
simultaneous use of AEDs. In an observational study involving
patients with LE and GAD-antibodies (n = 9) or VGKC-complex
antibodies (n = 10), there was a marked improvement in seizure
frequency in the latter group. But in the GAD-antibody group, no
patient became seizure free. GAD-antibodies, unlike those
against LGI1, remained elevated during treatments [66], and,
of course, target an intracellular antigen suggesting a lack of
direct pathogenicity. Accordingly, a case series of 112 patients
with unexplained adult onset epilepsy, showed GAD-antibodies
were found in six (5.4%) of which ﬁve received IT without
seizure freedom [68]. Supplementary Table 1C summarizes
studies describing the treatment of GAD-antibody associated
encephalitis.7. Discussion
In recent years, there has been accumulating evidence to
support an autoimmune aetiology for some patients with AED-
resistant seizures, typically in the context of an antibody-mediated
encephalopathy [22,28,37]. The molecular precision of the likely
pathogenic autoantibody implies that the study of any seizures
generated by these autoantibodies – not just those which are
clinically distinctive – may inform mechanisms of epileptogenesis,
and the therapeutic options. Therefore, any seizure disorder likely
to be caused by these antibodies is an example of an ‘autoimmune
epilepsy’. Yet it remains uncertain how these autoimmune
epilepsies should be treated. Consistently, early ITs, and
sometimes more aggressive regimes, produce better outcomes
[3,11,26,43,45]. However, to date, no randomized interventional
studies have been conducted. Such trials will be challenging to
implement for many reasons including the heterogeneous clinical
presentation of cases [29], the understandable reluctance of
clinicians to abstain from immediate and empirical treatments, the
absence of proven high-quality outcome measures other than
seizure frequency, and the sometimes considerable time lag
between onset of symptoms and diagnosis [2,7,8,25,48]. In the
absence of RCTs, high-quality observational studies characterized
by standardized and complete assessments of clinical outcomes
are of value. However, evidence from observational studies is not
without limitations. These include concomitant under-reported
use of varied AEDs [29], the absence of a placebo-treated group or
natural history cohort, small numbers in many studies, and the
likely publication bias from reporting of marked recoveries.
Another clear observation from this review is that patients with
autoimmune epilepsies are inconsistently phenotyped
[3,45,52,85]. For example, seizure semiologies were only rarely
described in detail. More importantly, outcome measures were
inconsistent, and while the administered ITs were described in all
papers, the details of AED administration were markedly under-
reported. For example, only 3 of the 11 (27%) VGKC-complex
antibody studies reviewed described whether AEDs were used
before IT, only 5 of 11 (45%) reported the number of AEDs
administered, and only 4 of 11 (36%) showed seizure frequency as
an outcome measure. For NMDAR-antibodies, the corresponding
percentages were 0%, 40% and 0%. Epilepsy-speciﬁc data must be
more consistently reported in future studies and a minimal dataset
might include longitudinal measures of mRS, seizure frequency,
autoantibodies plus use of IT and AEDs. This may create the basis
for the deﬁnition of IT-responsive antibody-associated epilepsies.
Although there is accumulating evidence for the presence of
antibodies in patients with refractory epilepsy [3,6,27–29,82],
there are several unanswered questions such as the pathogenic
role of these antibodies, the optimal methods used to identify
patients with epilepsy and autoantibodies, and there are only
paradigms for a clear IT-response in patients with more acute
encephalopathic syndromes [29]. With the exception of GAD-
antibody associated disorders, all other autoimmune conditions
described in this review are characterized by NSAbs: antibodies
that target extracellular domains of neuronal proteins located on
the cell membrane. The antibodies may therefore be capable of
exerting their pathological effects in the brain, but how these
antibodies gain access to the central nervous system, the
mechanisms by which they cause changes in the neuronal
networks and why they exert their pathology in speciﬁc regions
of the brain remains to be elucidated. Furthermore, whether the
marked intrathecal synthesis of antibodies in GAD [86] and
NMDAR-antibody [87] associated disorders drives the pathogenic
process requires further investigation.
The selection of patients for autoimmune evaluation requires a
high level of suspicion at initial consultation. In view of the fact
O.D. Bakpa et al. / Seizure 41 (2016) 26–4140that there are currently no universally agreed diagnostic criteria
for autoimmune epilepsies, it is difﬁcult to identify patients who
will beneﬁt from antibody screening. However, evidence from
observational studies suggests that high frequency of seizures,
psychiatric comorbidity and resistance to AEDs are useful
indicators. In conclusion, despite the lack of deﬁnitive RCTs, this
review provides evidence to suggest that early, often multiple, ITs
used in a graded fashion (see Fig. 1) are efﬁcacious and safe in
patients with autoimmune epilepsy.
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